Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Post by josameyeron Jun 22, 2011 9:17am

420 Views

Post# 18749047

recent discovery at the 147 zone.

I share the exitement with the potential of the current drill program.We have strong gold mineralization over an approximate 250 m strike length.The 2011 program to continue towards a 43-101 resource statement. Program is designed to test gold mineraliztion down plunge along highgrade ore shoots and along strike to the north. Five drills currently testing the 147 zone.The next bit of news should be, the expansion of the mil at Black Fox and a deferment of the Box Mine at this time. I am not sure, but does some of the trading at the present time, has something to do with the warrants being exersized? Nice to see some new postings Please DYODD. Cheers Josa.

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features